Zymeworks Inc. es una empresa de biopharmacia en fase de desarrollo clínico, dedicada a identificar, avanzar y llevar al mercado terapias biológicas ...
Zymeworks Inc. is a global, clinical-stage biopharmaceutical company headquartered in Canada (with public filings and historical sourcing also referencing a U.S. presence). The company is focused on the discovery, development, and, in some cases, commercialization support of multifunctional, engineered biological therapies aimed at improving outcomes for patients with difficult-to-treat cancers. ...Zymeworks Inc. is a global, clinical-stage biopharmaceutical company headquartered in Canada (with public filings and historical sourcing also referencing a U.S. presence). The company is focused on the discovery, development, and, in some cases, commercialization support of multifunctional, engineered biological therapies aimed at improving outcomes for patients with difficult-to-treat cancers.
Business model and strategy: Zymeworks is often described as a “royalty-driven” biotechnology organization that combines in-house R&D with a portfolio of licensed healthcare assets. This approach can allow the company to diversify technical risk across multiple programs while leveraging external partners for development, commercialization, and funding. The company also maintains industry alliances with major pharmaceutical and biotechnology companies, reflecting a collaborative model common to mid-cap clinical biotherapeutics.
Core products and pipeline: Based on the provided description, two primary experimental treatments are highlighted. Zanidatamab is a bispecific antibody currently in Phase 1/Phase 2 studies across multiple malignancy settings (including malignancies affecting the biliary tract, gastroesophageal region/adenocarcinomas, breast, and colon). ZW49 is an antibody-drug conjugate designed to target two sites on HER2; it is in Phase 1 trials for advanced or metastatic tumors expressing HER2. These assets illustrate Zymeworks’ emphasis on engineered targeting and multifunctionality, rather than conventional single-target biologics.
Partnerships and alliances: The company’s ecosystem includes collaborations and alliances with large pharma organizations (e.g., Merck Sharp & Dohme, Eli Lilly, Bristol-Myers Squibb, GlaxoSmithKline, Daiichi Sankyo, Janssen Biotech, BeiGene, and Exelixis are listed in the provided overview). Zymeworks also participates in cooperative research and licensing arrangements (including bispecific antibody exploration and development agreements referenced in the source materials). Such partnerships can support clinical progression, broaden trial reach, and align resources across geographies.
Scale and staffing: The provided data indicates roughly the mid-hundreds of employees (264 reported; other ranges cited in the material place the firm in the 201–500 bracket). This staffing level is consistent with a company running multiple early-to-mid clinical programs while maintaining internal engineering, discovery, and clinical development functions.
Cost and financial posture (high-level): Like many clinical-stage biotechs, Zymeworks’ economics are typically characterized by significant R&D investment, with profitability often not achieved during early development. The provided dataset includes several negative margin and cash-flow-related metrics (e.g., negative operating/net margins and negative operating cash flow metrics on an enterprise value basis), which aligns with a development-focused operating profile. In this context, capital access and partnership execution are often key to funding ongoing trials and program expansions.
Key people: Kenneth H. Galbraith serves as Chair and Chief Executive Officer. Another co-founder referenced in the provided materials is Ali Tehrani, who is associated with founding the company in 2003 and leading it through early clinical validation.
Looking forward (company “wishes” in practical terms): For Zymeworks, the central operational objective is to advance its lead candidates (including zanidatamab and ZW49) through clinical development, generate supportive efficacy and safety data, and convert pipeline promise into durable clinical and regulatory progress—ideally supported by strong partner execution and continued ability to fund development activities.
Plutux no es un asesor de inversiones. Los datos de mercado y el análisis generado por IA son solo informativos y educativos, no asesoramiento de inversión. Aviso legal
InteranualYoY significa Year-over-Year (interanual). Compara el último valor anual con el valor anual anterior para mostrar la fortaleza de la tendencia a largo plazo.
TrimestralQoQ significa Quarter-over-Quarter (intertrimestral). Compara el último trimestre con el trimestre inmediatamente anterior para mostrar cambios de impulso a corto plazo.
IngresosEl dinero total que entró por la puerta principal al vender cosas, antes de pagar una sola factura. Piensa en esto como el gran total de cada compra con tarjeta de los clientes. (YoY compara el rendimiento de este año con el del año pasado, mientras que QoQ compara los tres meses actuales con los tres anteriores).
$106.0M
+38.9%
+90.6%
Beneficio netoEl resultado final absoluto. Si la empresa pagara a cada proveedor, empleado, banquero y recaudador de impuestos, este es el dinero real que queda en su bolsillo al final del día.
$-81.1M
+33.9%
-1.9%
Margen brutoEl margen básico. Si venden unas zapatillas de 100 dólares, este porcentaje indica cuánto de ese precio es ganancia justo después de pagar el caucho y los cordones, pero antes de pagar el alquiler de la tienda o los anuncios de televisión.
+100.0%
0.0%
+648.5%
Margen operativoLa puntuación de eficiencia del 'trabajo diario'. De cada dólar que gasta un cliente, esto muestra cuántos centavos mantiene la empresa después de fabricar el producto Y pagar todos los gastos generales corporativos (como salarios, marketing y mantener las luces encendidas).
-87.3%
+51.4%
+53.0%
Margen netoEl porcentaje final que se lleva a casa. Cuando se eliminan todos los costos concebibles, impuestos y pagos de intereses, este es el número exacto de centavos que la empresa realmente se queda de cada dólar en ventas.
-76.6%
+52.4%
+46.5%
Flujo de caja libreEl santo grial del efectivo corporativo. Es el dinero físico gastable que queda después de que el negocio paga sus operaciones diarias Y compra las actualizaciones grandes y costosas (como nuevas fábricas o servidores) que necesita para sobrevivir. Este es el dinero 'libre' que pueden usar para pagar dividendos o recomprar acciones.
$-34.5M
+69.5%
+30.1%
Margen FCFLa tasa definitiva de conversión de efectivo. Muestra qué tan buena es la empresa para convertir ventas regulares directamente en efectivo frío, duro y gastable. Un porcentaje alto significa que el negocio es una auténtica máquina de imprimir dinero.
-32.6%
+78.0%
+63.3%
Deuda/PatrimonioEl indicador de riesgo financiero. Compara cuánto del imperio de la empresa se construyó con dinero prestado (préstamos) frente al dinero propio de los propietarios (accionistas). Un número alto significa que están muy apalancados y juegan un juego más arriesgado; un número bajo significa que juegan a lo seguro.
6.8%
+24.5%
+3108.6%
Ratio corrienteLa verificación de supervivencia de 12 meses. Simplemente compara el efectivo que tienen ahora mismo (más cosas que pueden convertirse rápidamente en efectivo) con las facturas inmediatas que absolutamente deben pagar este año. Una puntuación superior a 1 significa que tienen suficiente en la billetera para cubrir las próximas facturas sin entrar en pánico.
5.52x
+62.1%
-41.6%
Activos totalesEl tamaño absoluto del imperio de la empresa. Agrupa absolutamente todo lo valioso que poseen, desde el efectivo en la caja registradora y el inventario en el almacén, hasta las patentes de software en la bóveda y las fábricas en el suelo.
Operator: Good day, and thank you for standing by. Welcome to Zymeworks First Quarter 2026 Results Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Shrinal Inamdar, VP of Investor Relations. Your line is open.
Shrinal Inamdar: Thank you, operator. Good afternoon, everyone, and thank you for joining our first quarter 2026 results conference call. As usual, I'd like to remind you that we'll be making a number of forward-looking statements during this call, including, without limitation, those forward-looking statements identified in our slides and the accompanying oral commentary. These forward-looking statements are based upon our current expectations and various assumptions and are subject to the risks and uncertainties, including those associated with companies in our industry and at our stage of development. For a discussion of these risks and uncertainties, we refer you to our latest SEC filings as found on our website and as filed with the SEC. In a moment, I'll hand over the call to Ken Galbraith, our Chair and CEO, who will provide an overview of recent business updates. Ken will then hand the call over to Kristin Stafford, our Chief Financial Officer, to discuss our cash position and financial results for the first quarter 2026. Dr. Paul Moore will then provide a brief summary of new preclinical data disclosed at AACR on our pan-RAF ADCs. And following this, Dr. Sabeen Mekan, our SVP and Chief Medical Officer, will provide progress updates on both the Phase I clinical trial of ZW191 and ZW251. At the end of the call, Ken, Kristen, Sabine and Paul will be joined for a Q&A session with Scott Pashon, our Chief Business Officer; and Adam Chherowitz, Head of R&D. As a reminder, the audio and slides from this call will also be available on Zymeworks website later today. I'll now hand the call over to Ken.
Kenneth Galbraith: Thank you, Sal, and good afternoon, everyone. We're pleased to be reporting on further progress this quarter on both our wholly owned and partnered assets. The PDUFA date of August 25, 2026, for zanidatamab and first-line GEA in the U.S., together with the completion of an sBLA filing in China for first-line GEA marks an important inflection point and near-term foundational value-driving opportunity for Zymeworks. These regulatory milestones provide increasing visibility towards commercialization in first-line HER2-positive GEA and accompany continued clinical development in additional settings such as breast cancer, helping to establish a clear baseline for zanidatamab's value. If you didn't get a chance to tune in, we'd urge you to listen into Jazz's disclosures within their earnings call earlier this week on preparedness and launch activities for GEA in anticipation of an FDA approval later this year on or before the PDUFA date. With our partners, Jazz and B1, bringing established commercial …
